{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:43:29Z","timestamp":1778910209593,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["DZIF TTU-IICH-708.2 X"],"award-info":[{"award-number":["DZIF TTU-IICH-708.2 X"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virus Genes"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11262-017-1482-7","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T13:02:22Z","timestamp":1497963742000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer"],"prefix":"10.1007","volume":"53","author":[{"given":"Susanne M.","family":"Bailer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Funk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Ruzsics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"1482_CR1","doi-asserted-by":"crossref","unstructured":"A.J. Davison, Overview of classification. In Human Herpesviruses: Biology, Therapy and Immunoprophylaxis, ed. by A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley, et al. (Cambridge University Press; 2007)","DOI":"10.1017\/CBO9780511545313.002"},{"issue":"5","key":"1482_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nrg1066","volume":"4","author":"CE Thomas","year":"2003","unstructured":"C.E. Thomas, A. Ehrhardt, M.A. Kay, Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346\u2013358 (2003). doi: 10.1038\/nrg1066 .","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"1482_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"B.L. Liu, M. Robinson, Z.Q. Han, R.H. Branston, C. English, P. Reay et al., ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10(4), 292\u2013303 (2003). doi: 10.1038\/sj.gt.3301885 .","journal-title":"Gene Ther."},{"issue":"25","key":"1482_CR4","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"R.H. Andtbacka, H.L. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney et al., Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33(25), 2780\u20132788 (2015). doi: 10.1200\/JCO.2014.58.3377 .","journal-title":"J. Clin. Oncol."},{"issue":"7469","key":"1482_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature12519","volume":"502","author":"SG Hansen","year":"2013","unstructured":"S.G. Hansen, M. Piatak Jr., A.B. Ventura, C.M. Hughes, R.M. Gilbride, J.C. Ford et al., Immune clearance of highly pathogenic SIV infection. Nature 502(7469), 100\u2013104 (2013). doi: 10.1038\/nature12519 .","journal-title":"Nature"},{"issue":"1\u20132","key":"1482_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jphysparis.2011.11.003","volume":"106","author":"D Jerusalinsky","year":"2012","unstructured":"D. Jerusalinsky, M.V. Baez, A.L. Epstein, Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases. J. Physiol. Paris 106(1\u20132), 2\u201311 (2012). doi: 10.1016\/j.jphysparis.2011.11.003 .","journal-title":"J. Physiol. Paris"},{"issue":"1 Pt 1","key":"1482_CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0092-8674(80)90172-5","volume":"22","author":"ES Mocarski","year":"1980","unstructured":"E.S. Mocarski, L.E. Post, B. Roizman, Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversions. Cell 22(1 Pt 1), 243\u2013255 (1980).","journal-title":"Cell"},{"issue":"5763","key":"1482_CR8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/285333a0","volume":"285","author":"JR Smiley","year":"1980","unstructured":"J.R. Smiley, Construction in vitro and rescue of a thymidine kinase-deficient deletion mutation of herpes simplex virus. Nature 285(5763), 333\u2013335 (1980).","journal-title":"Nature"},{"issue":"20","key":"1482_CR9","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1073\/pnas.84.20.7213","volume":"84","author":"RR Spaete","year":"1987","unstructured":"R.R. Spaete, E.S. Mocarski, Insertion and deletion mutagenesis of the human cytomegalovirus genome. Proc. Nat. Acad. Sci. USA 84(20), 7213\u20137217 (1987)","journal-title":"Proc. Nat. Acad. Sci. USA"},{"issue":"2","key":"1482_CR10","first-page":"477","volume":"167","author":"WC Manning","year":"1988","unstructured":"W.C. Manning, E.S. Mocarski, Insertional mutagenesis of the murine cytomegalovirus genome: one prominent alpha gene (ie2) is dispensable for growth. Virology 167(2), 477\u2013484 (1988)","journal-title":"Virology"},{"issue":"18","key":"1482_CR11","doi-asserted-by":"crossref","first-page":"8794","DOI":"10.1073\/pnas.89.18.8794","volume":"89","author":"H Shizuya","year":"1992","unstructured":"H. Shizuya, B. Birren, U.J. Kim, V. Mancino, T. Slepak, Y. Tachiiri et al., Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc. Nat. Acad. Sci. USA 89(18), 8794\u20138797 (1992)","journal-title":"Proc. Nat. Acad. Sci. USA"},{"issue":"21","key":"1482_CR12","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1093\/nar\/26.21.4901","volume":"26","author":"Q Tao","year":"1998","unstructured":"Q. Tao, H.B. Zhang, Cloning and stable maintenance of DNA fragments over 300 kb in Escherichia coli with conventional plasmid-based vectors. Nucl. Acids Res. 26(21), 4901\u20134909 (1998)","journal-title":"Nucl. Acids Res."},{"issue":"8","key":"1482_CR13","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1128\/JVI.73.8.6405-6414.1999","volume":"73","author":"GA Smith","year":"1999","unstructured":"G.A. Smith, L.W. Enquist, Construction and transposon mutagenesis in Escherichia coli of a full-length infectious clone of pseudorabies virus, an alphaherpesvirus. J. Virol 73(8), 6405\u20136414 (1999)","journal-title":"J. Virol"},{"issue":"26","key":"1482_CR14","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1073\/pnas.94.26.14759","volume":"94","author":"M Messerle","year":"1997","unstructured":"M. Messerle, I. Crnkovic, W. Hammerschmidt, H. Ziegler, U.H. Koszinowski, Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc. Nat. Acad. Sci. USA 94(26), 14759\u201314763 (1997)","journal-title":"Proc. Nat. Acad. Sci. USA"},{"issue":"6","key":"1482_CR15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0168-9525(00)02015-1","volume":"16","author":"W Brune","year":"2000","unstructured":"W. Brune, M. Messerle, U.H. Koszinowski, Forward with BACs: new tools for herpesvirus genomics. Trends Genet. 16(6), 254\u2013259 (2000).","journal-title":"Trends Genet."},{"key":"1482_CR16","first-page":"41","volume":"325","author":"Z Ruzsics","year":"2008","unstructured":"Z. Ruzsics, U.H. Koszinowski, Mutagenesis of the cytomegalovirus genome. Curr. Top. Microbiol. Immunol. 325, 41\u201361 (2008).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1482_CR17","doi-asserted-by":"publisher","first-page":"971296","DOI":"10.1155\/2011\/971296","volume":"2011","author":"K Narayanan","year":"2011","unstructured":"K. Narayanan, Q. Chen, Bacterial artificial chromosome mutagenesis using recombineering. J. Biomed. Biotechnol. 2011, 971296 (2011). doi: 10.1155\/2011\/971296 .","journal-title":"J. Biomed. Biotechnol."},{"key":"1482_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/978-1-60761-652-8_30","volume":"634","author":"BK Tischer","year":"2010","unstructured":"B.K. Tischer, G.A. Smith, N. Osterrieder, En passant mutagenesis: a two step markerless red recombination system. Methods Mol. Biol. 634, 421\u2013430 (2010). doi: 10.1007\/978-1-60761-652-8_30 .","journal-title":"Methods Mol. Biol."},{"key":"1482_CR19","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","year":"2007","unstructured":"A. Arvin, G. Campadelli-Fiume, E. Mocarski, P.S. Moore, B. Roizman, et al. (eds.), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis (Cambridge University Press, Cambridge, 2007)"},{"issue":"Suppl B","key":"1482_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/12.suppl_B.9","volume":"12","author":"GB Elion","year":"1983","unstructured":"G.B. Elion, The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 12(Suppl B), 9\u201317 (1983)","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1482_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/v8030063","volume":"8","author":"G Campadelli-Fiume","year":"2016","unstructured":"G. Campadelli-Fiume, B. Petrovic, V. Leoni, T. Gianni, E. Avitabile, C. Casiraghi et al., Retargeting strategies for oncolytic herpes simplex viruses. Viruses. 8(3), 63 (2016). doi: 10.3390\/v8030063 .","journal-title":"Viruses."},{"issue":"5","key":"1482_CR22","doi-asserted-by":"publisher","first-page":"e64200","DOI":"10.1371\/journal.pone.0064200","volume":"8","author":"M Nygardas","year":"2013","unstructured":"M. Nygardas, H. Paavilainen, N. Muther, C.H. Nagel, M. Roytta, B. Sodeik et al., A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity. PLoS ONE 8(5), e64200 (2013). doi: 10.1371\/journal.pone.0064200 .","journal-title":"PLoS ONE"},{"key":"1482_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-4939-0428-0_4","volume":"1144","author":"CH Nagel","year":"2014","unstructured":"C.H. Nagel, A. Pohlmann, B. Sodeik, Construction and characterization of bacterial artificial chromosomes (BACs) containing herpes simplex virus full-length genomes. Methods Mol. Biol. 1144, 43\u201362 (2014). doi: 10.1007\/978-1-4939-0428-0_4 .","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"1482_CR24","doi-asserted-by":"publisher","first-page":"e1004957","DOI":"10.1371\/journal.ppat.1004957","volume":"11","author":"C Funk","year":"2015","unstructured":"C. Funk, M. Ott, V. Raschbichler, C.H. Nagel, A. Binz, B. Sodeik et al., The herpes simplex virus protein pUL31 escorts nucleocapsids to sites of nuclear egress, a process coordinated by its N-terminal domain. PLoS Pathog. 11(6), e1004957 (2015). doi: 10.1371\/journal.ppat.1004957 .","journal-title":"PLoS Pathog."},{"key":"1482_CR25","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/mtm.2016.18","volume":"3","author":"G Ungerechts","year":"2016","unstructured":"G. Ungerechts, S. Bossow, B. Leuchs, P.S. Holm, J. Rommelaere, M. Coffey et al., Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol. Ther. Methods Clin. Dev. 3, 16018 (2016). doi: 10.1038\/mtm.2016.18 .","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1482_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/OV.S66086","volume":"4","author":"NA Sokolowski","year":"2015","unstructured":"N.A. Sokolowski, H. Rizos, R.J. Diefenbach, Oncolytic virotherapy using herpes simplex virus: how far have we come? Oncol. Virother. 4, 207\u2013219 (2015). doi: 10.2147\/OV.S66086 .","journal-title":"Oncol. Virother."},{"issue":"7","key":"1482_CR27","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","volume":"11","author":"PR Buijs","year":"2015","unstructured":"P.R. Buijs, J.H. Verhagen, C.H. van Eijck, B.G. van den Hoogen, Oncolytic viruses: from bench to bedside with a focus on safety. Hum. Vaccin. Immunother. 11(7), 1573\u20131584 (2015). doi: 10.1080\/21645515.2015.1037058 .","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"1482_CR28","doi-asserted-by":"publisher","first-page":"e1005449","DOI":"10.1371\/journal.ppat.1005449","volume":"12","author":"DR Wilcox","year":"2016","unstructured":"D.R. Wilcox, R. Longnecker, The herpes simplex virus neurovirulence factor gamma34.5: revealing virus-host interactions. PLoS Pathog. 12(3), e1005449 (2016). doi: 10.1371\/journal.ppat.1005449 .","journal-title":"PLoS Pathog."},{"key":"1482_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/978-1-4614-7651-1_10","volume":"790","author":"C Krummenacher","year":"2013","unstructured":"C. Krummenacher, A. Carfi, R.J. Eisenberg, G.H. Cohen, Entry of herpesviruses into cells: the enigma variations. Adv. Exp. Med. Biol. 790, 178\u2013195 (2013). doi: 10.1007\/978-1-4614-7651-1_10 .","journal-title":"Adv. Exp. Med. Biol."},{"key":"1482_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2016.01.010","volume":"18","author":"EE Heldwein","year":"2016","unstructured":"E.E. Heldwein, gH\/gL supercomplexes at early stages of herpesvirus entry. Curr. Opin. Virol. 18, 1\u20138 (2016). doi: 10.1016\/j.coviro.2016.01.010 .","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"1482_CR31","doi-asserted-by":"publisher","first-page":"e1004907","DOI":"10.1371\/journal.ppat.1004907","volume":"11","author":"V Gatta","year":"2015","unstructured":"V. Gatta, B. Petrovic, G. Campadelli-Fiume, The engineering of a novel ligand in gH confers to HSV an expanded tropism independent of gD activation by its receptors. PLoS Pathog. 11(5), e1004907 (2015). doi: 10.1371\/journal.ppat.1004907 .","journal-title":"PLoS Pathog."},{"issue":"4","key":"1482_CR32","doi-asserted-by":"publisher","first-page":"e1006352","DOI":"10.1371\/journal.ppat.1006352","volume":"13","author":"B Petrovic","year":"2017","unstructured":"B. Petrovic, T. Gianni, V. Gatta, G. Campadelli-Fiume, Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. PLoS Pathog. 13(4), e1006352 (2017). doi: 10.1371\/journal.ppat.1006352 .","journal-title":"PLoS Pathog."},{"key":"1482_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.coviro.2015.03.015","volume":"13","author":"CA Alvarez-Breckenridge","year":"2015","unstructured":"C.A. Alvarez-Breckenridge, B.D. Choi, C.M. Suryadevara, E.A. Chiocca, Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. Curr Opin Virol. 13, 25\u201332 (2015). doi: 10.1016\/j.coviro.2015.03.015 .","journal-title":"Curr Opin Virol."},{"issue":"6","key":"1482_CR34","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/mt.2011.65","volume":"19","author":"A Melcher","year":"2011","unstructured":"A. Melcher, K. Parato, C.M. Rooney, J.C. Bell, Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther. 19(6), 1008\u20131016 (2011). doi: 10.1038\/mt.2011.65 .","journal-title":"Mol. Ther."},{"key":"1482_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ebiom.2016.01.022","volume":"5","author":"A Pourchet","year":"2016","unstructured":"A. Pourchet, S.R. Fuhrmann, K.A. Pilones, S. Demaria, A.B. Frey, M. Mulvey et al., CD8(+) T-cell immune evasion enables oncolytic virus immunotherapy. EBioMedicine. 5, 59\u201367 (2016). doi: 10.1016\/j.ebiom.2016.01.022","journal-title":"EBioMedicine."},{"issue":"8","key":"1482_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"B.D. Lichty, C.J. Breitbach, D.F. Stojdl, J.C. Bell, Going viral with cancer immunotherapy. Nat. Rev. Cancer 14(8), 559\u2013567 (2014). doi: 10.1038\/nrc3770 .","journal-title":"Nat. Rev. Cancer"},{"key":"1482_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coviro.2015.06.005","volume":"13","author":"RS Coffin","year":"2015","unstructured":"R.S. Coffin, From virotherapy to oncolytic immunotherapy: where are we now? Curr. Opin. Virol. 13, 93\u2013100 (2015). doi: 10.1016\/j.coviro.2015.06.005 .","journal-title":"Curr. Opin. Virol."},{"issue":"13","key":"1482_CR38","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"R.H. Andtbacka, M. Ross, I. Puzanov, M. Milhem, F. Collichio, K.A. Delman et al., Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann. Surg. Oncol. 23(13), 4169\u20134177 (2016). doi: 10.1245\/s10434-016-5286-0 .","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"1482_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252\u2013264 (2012). doi: 10.1038\/nrc3239 .","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"1482_CR40","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"I. Puzanov, M.M. Milhem, D. Minor, O. Hamid, A. Li, L. Chen et al., Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34(22), 2619\u20132626 (2016). doi: 10.1200\/JCO.2016.67.1529 .","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"1482_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"S.J. Russell, K.W. Peng, J.C. Bell, Oncolytic virotherapy. Nat. Biotechnol. 30(7), 658\u2013670 (2012). doi: 10.1038\/nbt.2287 .","journal-title":"Nat. Biotechnol."},{"key":"1482_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/OV.S66217","volume":"5","author":"KJ Allan","year":"2016","unstructured":"K.J. Allan, D.F. Stojdl, S.L. Swift, High-throughput screening to enhance oncolytic virus immunotherapy. Oncolytic Virother. 5, 15\u201325 (2016). doi: 10.2147\/OV.S66217 .","journal-title":"Oncolytic Virother."},{"key":"1482_CR43","doi-asserted-by":"publisher","first-page":"824630","DOI":"10.1155\/2014\/824630","volume":"2014","author":"B Dong","year":"2014","unstructured":"B. Dong, D.S. Zarlenga, X. Ren, An overview of live attenuated recombinant pseudorabies viruses for use as novel vaccines. J. Immunol. Res. 2014, 824630 (2014). doi: 10.1155\/2014\/824630 .","journal-title":"J. Immunol. Res."},{"key":"1482_CR44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/978-1-4419-1132-2_10","volume":"655","author":"P Marconi","year":"2009","unstructured":"P. Marconi, R. Argnani, A.L. Epstein, R. Manservigi, HSV as a vector in vaccine development and gene therapy. Adv. Exp. Med. Biol. 655, 118\u2013144 (2009). doi: 10.1007\/978-1-4419-1132-2_10 .","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"1482_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jdermsci.2009.10.014","volume":"57","author":"D Watanabe","year":"2010","unstructured":"D. Watanabe, Medical application of herpes simplex virus. J. Dermatol. Sci. 57(2), 75\u201382 (2010). doi: 10.1016\/j.jdermsci.2009.10.014 .","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"1482_CR46","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1128\/JVI.78.5.2255-2264.2004","volume":"78","author":"U Karrer","year":"2004","unstructured":"U. Karrer, M. Wagner, S. Sierro, A. Oxenius, H. Hengel, T. Dumrese et al., Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J. Virol. 78(5), 2255\u20132264 (2004)","journal-title":"J. Virol."},{"issue":"8","key":"1482_CR47","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.4049\/jimmunol.1202665","volume":"190","author":"B Bolinger","year":"2013","unstructured":"B. Bolinger, S. Sims, G. O\u2019Hara, C. de Lara, E. Tchilian, S. Firner et al., A new model for CD8+\u00a0T cell memory inflation based upon a recombinant adenoviral vector. J. Immunol. 190(8), 4162\u20134174 (2013). doi: 10.4049\/jimmunol.1202665 .","journal-title":"J. Immunol."},{"issue":"2","key":"1482_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.it.2011.11.005","volume":"33","author":"GA O\u2019Hara","year":"2012","unstructured":"G.A. O\u2019Hara, S.P. Welten, P. Klenerman, R. Arens, Memory T cell inflation: understanding cause and effect. Trends Immunol. 33(2), 84\u201390 (2012). doi: 10.1016\/j.it.2011.11.005 .","journal-title":"Trends Immunol."},{"issue":"6274","key":"1482_CR49","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1126\/science.aac9475","volume":"351","author":"SG Hansen","year":"2016","unstructured":"S.G. Hansen, H.L. Wu, B.J. Burwitz, C.M. Hughes, K.B. Hammond, A.B. Ventura et al., Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E. Science 351(6274), 714\u2013720 (2016). doi: 10.1126\/science.aac9475 .","journal-title":"Science"},{"issue":"11","key":"1482_CR50","doi-asserted-by":"publisher","first-page":"e1006014","DOI":"10.1371\/journal.ppat.1006014","volume":"12","author":"BJ Burwitz","year":"2016","unstructured":"B.J. Burwitz, D. Malouli, B.N. Bimber, J.S. Reed, A.B. Ventura, M.H. Hancock et al., Cross-species rhesus cytomegalovirus infection of cynomolgus macaques. PLoS Pathog. 12(11), e1006014 (2016). doi: 10.1371\/journal.ppat.1006014 .","journal-title":"PLoS Pathog."},{"issue":"7142","key":"1482_CR51","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nature05762","volume":"447","author":"ES Barton","year":"2007","unstructured":"E.S. Barton, D.W. White, J.S. Cathelyn, K.A. Brett-McClellan, M. Engle, M.S. Diamond et al., Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447(7142), 326\u2013329 (2007). doi: 10.1038\/nature05762 .","journal-title":"Nature"},{"issue":"5","key":"1482_CR52","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.4049\/jimmunol.1302523","volume":"193","author":"PC Beverley","year":"2014","unstructured":"P.C. Beverley, Z. Ruzsics, A. Hey, C. Hutchings, S. Boos, B. Bolinger et al., A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis. J Immunol. 193(5), 2306\u20132316 (2014). doi: 10.4049\/jimmunol.1302523 .","journal-title":"J Immunol."},{"issue":"6","key":"1482_CR53","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00281-014-0441-9","volume":"36","author":"I Brizic","year":"2014","unstructured":"I. Brizic, T. Lenac Rovis, A. Krmpotic, S. Jonjic, MCMV avoidance of recognition and control by NK cells. Semin Immunopathol. 36(6), 641\u2013650 (2014). doi: 10.1007\/s00281-014-0441-9 .","journal-title":"Semin Immunopathol."},{"issue":"5","key":"1482_CR54","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.V100.5.1755.h81702001755_1755_1764","volume":"100","author":"A Moosmann","year":"2002","unstructured":"A. Moosmann, N. Khan, M. Cobbold, C. Zentz, H.J. Delecluse, G. Hollweck et al., B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 100(5), 1755\u20131764 (2002).","journal-title":"Blood"},{"key":"1482_CR55","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3389\/fimmu.2015.00598","volume":"6","author":"S Ameres","year":"2015","unstructured":"S. Ameres, X. Liang, M. Wiesner, J. Mautner, A. Moosmann, A diverse repertoire of CD4 T cells targets the immediate-early 1 protein of human cytomegalovirus. Front. Immunol. 6, 598 (2015). doi: 10.3389\/fimmu.2015.00598 .","journal-title":"Front. Immunol."},{"issue":"7","key":"1482_CR56","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/eji.200425936","volume":"35","author":"M Wiesner","year":"2005","unstructured":"M. Wiesner, C. Zentz, M.H. Hammer, M. Cobbold, F. Kern, H.J. Kolb et al., Selection of CMV-specific CD8+ and CD4+\u00a0T cells by mini-EBV-transformed B cell lines. Eur. J. Immunol. 35(7), 2110\u20132121 (2005). doi: 10.1002\/eji.200425936 .","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"1482_CR57","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/sj.gt.3302714","volume":"13","author":"E Hettich","year":"2006","unstructured":"E. Hettich, A. Janz, R. Zeidler, D. Pich, E. Hellebrand, B. Weissflog et al., Genetic design of an optimized packaging cell line for gene vectors transducing human B cells. Gene Ther. 13(10), 844\u2013856 (2006). doi: 10.1038\/sj.gt.3302714 .","journal-title":"Gene Ther."},{"issue":"10","key":"1482_CR58","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/gt.2011.45","volume":"18","author":"A Gimenez-Cassina","year":"2011","unstructured":"A. Gimenez-Cassina, R. Wade-Martins, S. Gomez-Sebastian, J.C. Corona, F. Lim, J. Diaz-Nido, Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector. Gene Ther. 18(10), 1015\u20131019 (2011). doi: 10.1038\/gt.2011.45 .","journal-title":"Gene Ther."},{"key":"1482_CR59","doi-asserted-by":"publisher","first-page":"28644","DOI":"10.1038\/srep28644","volume":"6","author":"MM Lufino","year":"2016","unstructured":"M.M. Lufino, P.A. Edser, M.A. Quail, S. Rice, D.J. Adams, R. Wade-Martins, The infectious BAC genomic DNA expression library: a high capacity vector system for functional genomics. Sci. Rep. 6, 28644 (2016). doi: 10.1038\/srep28644 .","journal-title":"Sci. Rep."},{"key":"1482_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020431","author":"AF Meier","year":"2017","unstructured":"A.F. Meier, M. Suter, E.M. Schraner, B.M. Humbel, K. Tobler, M. Ackermann et al., Transfer of anti-rotavirus antibodies during pregnancy and in milk following maternal vaccination with a herpes simplex virus type-1 amplicon vector. Int. J. Mol. Sci. (2017). doi: 10.3390\/ijms18020431","journal-title":"Int. J. Mol. Sci."}],"container-title":["Virus Genes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11262-017-1482-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-017-1482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-017-1482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T13:05:11Z","timestamp":1602335111000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11262-017-1482-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1007\/s11262-017-1482-7","relation":{},"ISSN":["0920-8569","1572-994X"],"issn-type":[{"value":"0920-8569","type":"print"},{"value":"1572-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]}}}